Literature DB >> 17552524

Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies.

Puneet Srivastava1, Jharna Barman, Wimal Pathmasiri, Oleksandr Plashkevych, Małgorzata Wenska, Jyoti Chattopadhyaya.   

Abstract

Two unusual reactions involving the 5-hexenyl or the 6-heptenyl radical cyclization of a distant double bond at C4' and the radical center at C2' of the ribofuranose ring of thymidine have been used as key steps to synthesize North-type conformationally constrained cis-fused bicyclic five-membered and six-membered carbocyclic analogues of LNA (carbocyclic-LNA-T) and ENA (carbocyclic-ENA-T) in high yields. Their structures have been confirmed unambiguously by long range 1H-13C NMR correlation (HMBC), TOCSY, COSY, and NOE experiments. The carbocyclic-LNA-T and carbocyclic-ENA-T were subsequently incorporated into the antisense oligonucleotides (AONs) to show that they enhance the Tm of the modified AON/RNA heteroduplexes by 3.5-5 degrees C and 1.5 degrees C/modification for carbocyclic-LNA-T and carbocyclic-ENA-T, respectively. Whereas the relative RNase H cleavage rates with carbocyclic-LNA-T, carbocyclic-ENA-T, aza-ENA-T, and LNA-T modified AON/RNA duplexes were found to be very similar to that of the native counterpart, irrespective of the type and the site modification in the AON strand, a single incorporation of carbocyclic-LNA and carbocyclic-ENA into AONs leads to very much more enhanced nuclease stability in the blood serum (stable >48 h) as compared to that of the native (fully degraded <3 h) and the LNA-modified AONs (fully degraded <9 h) and aza-ENA ( approximately 85% stable in 48 h). Clearly, remarkably enhanced lifetimes of these carbocyclic-modified AONs in the blood serum may produce the highly desired pharmacokinetic properties because of their unique stability and consequently a net reduction of the required dosage. This unique quality as well as their efficient use as the AON in the RNase H-promoted cleavage of the target RNA makes our carbocyclic-LNA and carbocyclic-ENA modifications excellent candidates as potential antisense therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552524     DOI: 10.1021/ja071106y

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  10 in total

Review 1.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

2.  In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts.

Authors:  Orf Mook; Jeroen Vreijling; Suzy L Wengel; Jesper Wengel; Chuanzheng Zhou; Jyoti Chattopadhyaya; Frank Baas; Kees Fluiter
Journal:  Artif DNA PNA XNA       Date:  2010-07

3.  Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs.

Authors:  Jiaxin Hu; Keith T Gagnon; Jing Liu; Jonathan K Watts; Jeja Syeda-Nawaz; C Frank Bennett; Eric E Swayze; John Randolph; Jyoti Chattopadhyaya; David R Corey
Journal:  Biol Chem       Date:  2011-02-07       Impact factor: 3.915

4.  An exocyclic methylene group acts as a bioisostere of the 2'-oxygen atom in LNA.

Authors:  Punit P Seth; Charles R Allerson; Andres Berdeja; Andrew Siwkowski; Pradeep S Pallan; Hans Gaus; Thazha P Prakash; Andrew T Watt; Martin Egli; Eric E Swayze
Journal:  J Am Chem Soc       Date:  2010-10-27       Impact factor: 15.419

5.  Functionalized 2'-amino-alpha-L-LNA: directed positioning of intercalators for DNA targeting.

Authors:  T Santhosh Kumar; Andreas S Madsen; Michael E Østergaard; Sujay P Sau; Jesper Wengel; Patrick J Hrdlicka
Journal:  J Org Chem       Date:  2009-02-06       Impact factor: 4.354

6.  Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

Authors:  Keith T Gagnon; Hannah M Pendergraff; Glen F Deleavey; Eric E Swayze; Pierre Potier; John Randolph; Eric B Roesch; Jyoti Chattopadhyaya; Masad J Damha; C Frank Bennett; Christophe Montaillier; Marc Lemaitre; David R Corey
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

7.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

8.  A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity.

Authors:  Jesper B Bramsen; Maria B Laursen; Anne F Nielsen; Thomas B Hansen; Claus Bus; Niels Langkjaer; B Ravindra Babu; Torben Højland; Mikhail Abramov; Arthur Van Aerschot; Dalibor Odadzic; Romualdas Smicius; Jens Haas; Cordula Andree; Jharna Barman; Malgorzata Wenska; Puneet Srivastava; Chuanzheng Zhou; Dmytro Honcharenko; Simone Hess; Elke Müller; Georgii V Bobkov; Sergey N Mikhailov; Eugenio Fava; Thomas F Meyer; Jyoti Chattopadhyaya; Marino Zerial; Joachim W Engels; Piet Herdewijn; Jesper Wengel; Jørgen Kjems
Journal:  Nucleic Acids Res       Date:  2009-03-12       Impact factor: 16.971

9.  A bridged nucleic acid, 2',4'-BNA COC: synthesis of fully modified oligonucleotides bearing thymine, 5-methylcytosine, adenine and guanine 2',4'-BNA COC monomers and RNA-selective nucleic-acid recognition.

Authors:  Yasunori Mitsuoka; Tetsuya Kodama; Ryo Ohnishi; Yoshiyuki Hari; Takeshi Imanishi; Satoshi Obika
Journal:  Nucleic Acids Res       Date:  2009-01-09       Impact factor: 16.971

10.  Optimization of an AMBER force field for the artificial nucleic acid, LNA, and benchmarking with NMR of L(CAAU).

Authors:  David E Condon; Ilyas Yildirim; Scott D Kennedy; Brendan C Mort; Ryszard Kierzek; Douglas H Turner
Journal:  J Phys Chem B       Date:  2014-01-24       Impact factor: 2.991

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.